Kazia Reports Over 50% Cancer Cell Reduction In Early Data From Breast Cancer Trial, Stock Jumps

benzinga.com/news/health-care/25/07/%2Fkazia-reports-over-50-cancer-cell-reduction-in-early-data-from-breast-cancer-trial-stock-jumps

Kazia Therapeutics (NASDAQ:KZIA) on Wednesday reported preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab), and standard chemotherapy after completing Cycle 1 (21 days) of…

This story appeared on benzinga.com, 2025-07-09 18:47:09.
The Entire Business World on a Single Page. Free to Use →